-+ 0.00%
-+ 0.00%
-+ 0.00%

MILESTONE PHARMACEUTICALS: CURRENTLY PURSUING SINGLE-STUDY SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) REGISTRATION PATHWAY FOR TREATMENT OF AFIB-RVR

路透·08/21/2026 12:00:00

登錄查看新聞詳情